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Constant intraperitoneal 5-fluorouracil infusion through a 
totally implanted system 
Five-day continuous intraperitoneal (ip) infusions of 5-fluorouracil (FU) were injected into five 
patients as part of a phase I clinical pharmacology study. They received 20 courses through a 
totally implanted catheter/ injection port system. Six courses are evaluable for kinetic parameters 
and all courses are evaluable for toxicity. In each course a 2 to 3 log FU concentration 
differential in favor of the peritoneal cavity was achieved and maintained. Steady-state venous 
plasma FU concentrations averaged 0.34 pM, whereas steady-state ip FU concentrations 
averaged 697 I.LM. Mean total body clearance (TBC) in these patients was 18.4 Ilmin and mean 
permeability-area (PA) product for diffusion from the peritoneum was 13.7 ml/mm. Mean TBC 
of 20 Ilmin with ip FU infusion was observed in one patient who also received a 24-hr IV FU 
infusion for comparison. The TBC during the later infusion was 5.9 llmin. In this patient, 
calculations indicate 75% extraction of drug during the passage from the peritoneum to the 
systemic circulation, presumably representing in large part hepatic extraction of FU taken into 
the portal venous circulation. lp constant infusion and bolus kinetics were compared in one 
patient. TBC for the ip bolus was 14.3 Ilmin, which was approximately half of the TBC of 29.5 
Ilmin determined during the 5-day constant ip infusion. Thus constant ip infusion of FU (1 
gm/day) can provide an improved regional advantage over bolus ip FU because of an increased 
TBC. Toxicity was acceptable in all courses. Dose limiting toxicity was regional, namely 
moderate chemical peritonitis seen in two of the five patients on repeated courses. There was no 
myelosuppression, alopecia, nausea, or vomiting. There were no infectious complications. The 
only patient with measurable disease had an objective response in hepatic metastases from 
gastric cancer. The implanted device was well tolerated and facilitated peritoneal fluid 
sampling. 
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Disseminated intraperitoneal (ip) cancer oc- 
curs frequently in gastrointestinal and gyneco- 
logic malignancies. Malignant ascites can be a 
major problem in other cancers as well. The 
unique restricted volume of distribution in the 
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peritoneal cavity makes it possible to devise 
regimens to provide selective concentrated drug 
exposure by ip injection. The kinetic rationale 
for ip injection of antineoplastic drugs has been 
elegantly delineated by Dedrick et al.' They 
have shown that, at steady state, the selective 
advantage (Rd) of a direct drug infusion into the 
peritoneal cavity relates directly to the total 
body clearance (TBC) of the drug infused and 
inversely to the permeability-area product (PA), 
a measure of peritoneal clearance, of the 
peritoneal surface exposed. 8' 26 Initial pilot stud- 
ies of ip chemotherapy in man used 5- 
fluorouracil (FU),26. " methotrexate,15' " ad- 
riamycin,24 melphelan," and cisplatin.16, 17, 20. 
The studies demonstrated that these drugs can 
be injected ip with acceptable regional toxicity 
and that the drug concentrations achieved in the 
peritoneal cavity can be 10 to 1000 times as 
high as in the plasma. Drugs with significant 
hepatic extraction are ideal since a portion of 
such drugs may be metabolized by the liver 
through portal venous uptake before reaching 
the sytemic circulation. This first pass effect 
would be expected to increase the TBC of the 
drug and maximize the difference between 
plasma and peritoneal fluid drug concentration. 
Other studies have generally used exchanges 
of large volumes of drug containing solutions 
injected through Tenkhoff peritoneal dialysis 
catheters. Since antimetabolites generally in- 
duce cytotoxicity as a function of duration of 
exposure above critical concentrations5 we have 
investigated protracted infusions of the antime- 
tabolite FU as a means of selectively sustaining 
high regional drug levels in the peritoneal cav- 
ity, whereas the lower systemic levels achieved 
may avoid systemic toxicity. In addition, to cir- 
cumvent the inconvenience and morbidity as- 
sociated with indwelling peritoneal catheters, 
we have used a new, totally implanted silastic 
catheter/port system that facilitates peritoneal 
fluid sampling yet obviates the need for dressing 
changes and may avoid potential infectious 
complications associated with chronic exter- 
nalized catheters. 
Methods 
Our subjects were five male patients with his- 
tologic proof of malignancy (four colon cancer, 
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one gastric cancer) aged 28 to 62. Two patients 
had residual macroscopic but nonmeasurable, 
intra-abdominal extrahepatic cancer after resec- 
tion of a primary colon carcinoma and two pa- 
tients with Dukes C2 lesions were treated as part 
of an adjuvant study. The fifth patient had unre- 
sectable gastric cancer with measurable liver 
metastases by computerized tomography (CT) 
and peritoneal seeding with tumor and symp- 
tomatic malignant ascites. No patient had re- 
ceived chemotherapy. 
Tenkhoff (four patients) or Toronto (one pa- 
tient) Silastic peritoneal dialysis catheters were 
implanted in the abdominal cavity through a 
subcutaneous tunnel under local anesthesia and 
attached to an injection port (Pharmacia Nu 
Tech) placed subcutaneously and affixed to the 
fascia of the lower anterior chest wall. The port 
consists of a low profile stainless steel cylindri- 
cal chamber with a self-sealing silicone rubber 
septum. An IVAC 530 infusion pump (IVAC 
Corp.), or an IMED 960 infusion pump (IMED 
Corp.) and Luer-lok extension tubing were used 
for drug infusions. A three-way stopcock was 
inserted into the infusion line and attached to a 
Huber-point needle bent at 90° so that the hub of 
the needle lay parallel to the skin when inserted 
percutaneously into the port. The needle and 
adjacent tubing were placed under sterile con- 
ditions and secured with steri-strips (3M Corp.) 
and op-site (Acme United Corp.) for the 5-day 
infusion. At the completion of an infusion the 
needle was removed and no further maintenance 
was required. This methodology had been used 
successfully for continuous intravenous infu- 
sions with another implanted injection port 
system." 
Before therapy, 1.5 1 lactated Ringers (LR) 
solution was infused into the abdomen over 90 
min followed by a constant infusion of LR at 42 
ml/hr. This rate was selected based on tech- 
netium 99m sulfur colloid (TcSC) isotopic dilu- 
tion studies in which only a 10% to 20% change 
in ip volume was found on day 5 from day 1 
using this initial volume and subsequent rate of 
infusion. In addition, in one patient the abdo- 
men was drained and a volume of 1.3 1 recov- 
ered after completing the 5-day infusion. The ip 
distribution of the fluid was determined by 
radionuclide scan.16. 17' 29 Before chemother- 
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apy, 1 mCi of TcSC was injected ip and the 
patients scanned after 1 hr of ambulation. Pa- 
tients were candidates for pharmacology studies 
if the scan demonstrated free distribution of the 
radiopharmaceutical. 
The ip infusion therapy consisted of 1 gm FU 
each day (1 gm FU in 1 LR injected ip at 42 
ml/hr) for 5 days repeated monthly. Simulta- 
neous peritoneal fluid and venous plasma sam- 
ples were obtained twice daily beginning 12 hr 
after initiation of the ip infusion. Patients ambu- 
lated for one hour before peritoneal fluid sam- 
pling. Peritoneal fluid samples (5 ml) for FU 
assay were obtained through the three-way 
stopcock after withdrawing 20 ml peritoneal 
fluid to flush the catheter and avoid sampling 
error. The 25-ml volume was then replaced and 
the infusion-rate resumed in an effort to main- 
tain a constant ip volume. The adequacy of this 
sampling technique was determined in two pa- 
tients in whom random simultaneous samples 
were obtained from a second temporary silastic 
catheter placed into the peritoneal cavity on the 
contralateral side. Under these circumstances 
the ip FU concentration determined from the 
two sites was equivalent (within 5%). 
A total of 20 ip FU infusions were injected 
into the five patients. Six courses were evalu- 
able for kinetic studies, and all courses were 
evaluable for toxicity. One patient was evalu- 
able for response. In addition to the 5-day ip 
infusion one patient received a 24-hr IV infu- 
sion of FU (1 gm/24 hr) and a second patient 
received an ip bolus of FU (1 gm over 1 min) 
for comparison with the ip infusion kinetic data. 
FU was assayed by a HPLC assay. To mea- 
sure FU concentrations greater than 1 gg/ml, a 
200-,u1 sample of plasma or peritoneal fluid was 
added to 400 Al methanol and 40 pi internal 
standard solution (10 ,ug 5-chlorouraci1/40 4u1). 
The mixture was vortexed and centrifuged at 
4000 rpm for 15 min at 4°. The supernatant (1 to 
10 /11) was injected for HPLC analysis. Samples 
were analyzed on a RCM-100 Radial-Pak C18 
column system (Waters) using a 0.01M am- 
monium phosphate (pH = 6.7) mobile phase. 
The flow rate was set at 2 ml/min and peak 
detection was accomplished with a Waters 
Model 440 UV-VIS detector with a 254 mg 
filter. Calibration curves were constructed by 
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Fig. 1. Concurrent peritoneal fluid and plasma 
fluorouracil levels during continuous ip infusions in 
five patients. Each patient is represented by a symbol 
of different configuration (note repeated course in 
one patient, empty box and solid triangle) and each 
point represents the mean of two samples obtained on 
each of 5 days. 
plotting the ratio of the peak height of FU to that 
of the internal standard as a function of the 
plasma FU concentration. This assay has a co- 
efficient of variation4 of 5% over the range from 
5 to 40 ,u,g/m1 and is accurate to within 5% of 
the theoretical values. 
To measure FU concentrations under 1 /kg/ 
ml, 1 ml plasma, or peritoneal fluid was added 
to 50 /A internal standard solution (500 ng 
5-chlorouracil) and 2 ml saturated ammonium 
sulfate. The mixture was vortexed and extracted 
twice with 8 ml ethyl acetate by shaking for 10 
min at room temperature. The samples were 
then centrifuged at 3000 rpm for 10 min at room 
temperature and the pooled ethyl acetate frac- 
tions were transferred to conical-bottomed glass 
tubes. After adding 400 1.1,1 5N KOH, the drug 
was back-extracted by shaking for 5 min. The 
samples were again centrifuged (2000 rpm, 15 
min, room temperature) and the ethyl acetate 
phase discarded. The alkaline aqueous phase, 1 
to 20 sul, was injected for HPLC analysis with 
an Altex Ultrasphere-ODS, 5 s column (Beck- 
man). The mobile phase was a 0.1M ammonium 
phosphate buffer (pH = 6.7), and the flow rate 
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Table I. Kinetic parameters for continuous ip infusion of 5-fluorouracil 1 gm/day for 5 days 
(six courses, five patients) 
CV = Coefficient of variation. 
was as described above. Accuracy and precision 
studies with drug-spiked control plasma at a 
final concentration of 100 ng FU/ml resulted in 
a coefficient of variation' of 8.8%, whereas the 
mean of these estimates was within 2% of their 
theoretic value. 
Results 
Concurrent peritoneal fluid and plasma FU 
levels obtained during the continuous ip infu- 
sion are shown in Fig. 1. For the entire group, 
the plasma levels ranged from 0.13 to 1.1 IA, M, 
whereas the ip levels ranged from 0.12 to 2.3 
mM. This 2-3 log differential was maintained 
over the 5-day course in each case. 
The kinetic parameters evaluated during the 
5-day ip infusions in the five patients are listed 
in Table I. The mean plasma FU concentration, 
for individual courses ranged from 0.18 to 0.58 
AM. This mean plasma concentration repre- 
sents the steady-state venous plasma concentra- 
tion (C). The coefficient of variation' for 
in each course ranged from 18% to 68% 
(mean 32%; median 25.5%). The mean C, for 
the entire group was 0.34 AM (median 0.29 
AM). The mean peritoneal fluid FU concentra- 
tion for individual courses ranged from 176 to 
2004 M. The mean concentration over the 
5-day infusion represents the steady-state ip FU 
concentration (CO for that course. The co- 
efficient of variation for for individual 
courses ranged from 9% to 35% (mean 24%; 
din. Pharmacol. Ther. 
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median 26.5%). The mean Css for the entire 
group was 697 AM (median 532 A,M). 
Total body clearance (TBC) was calculated 
from the ratio of the constant infusion dose rate 
and the venous plasma steady-state concentra- 
tion. In these six treatment courses TBC aver- 
aged 18.4 //min (median 18.5 //min) The per- 
meability area product (PA) was determined 
from steady-state levels (C and C) and the 
TBC.26 The mean PA in these patients was 13.7 
ml/min (median 10 ml/min). 
The selective regional advantage (Rd) of ip 
infusion FU was directly determined as the ratio 
of C, to and also calculated from values 
derived for TBC and PA.s' " Both methods 
gave equivalent results. In these patients the 
mean Rd was 2559 (median 1066). 
Forty-eight hours before his second course of 
ip FU, patient 1 received a 24-hr intravenous 
infusion of FU (1 gm/24 hr) after loading the 
abdomen as described for the ip infusion treat- 
ment followed by constant infusion of LR ip at 
42 ml/hr. Peritoneal fluid and venous blood 
samples were obtained during the infusion and 
assayed for FU. Based on the formula derived 
by Collins et al.' the extraction of FU by the 
liver and peritoneal surface was calculated from 
steady-state venous plasma levels obtained from 
the intravenous and subsequent ip infusions. In 
this case the extraction of FU was found to be 
75%. TBC during the 24-hr intravenous infu- 
sion was calculated as described above and 
Venous Peritoneal 













1 0.32 18% 176 27% 16.6 30.2 550 
0.22 27% 243 16% 24.1 21.8 1108 
2 0.26 30% 2004 9% 20.4 2.6 7852 
3 0.51 68% 475 31% 10.4 11.1 939 
4 0.18 22% 694 35% 29.5 7.6 3880 
5 0.58 24% 588 26% 9.2 9.0 1023 
Group mean 0.34 (0.16) 32% (18.3) 697 (670) 24% (9.7) 18.4 (7.9) 13.7 (10.3) 2559 (2860) 
(± SD) 
Group median 0.29 25.5% 532 26.5% 18.5 10.1 1066 
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Table II. Drug related toxicity associated with intraperitoneal infusion of 5-fluorouracil 1 gm/day 







*All patients experienced mild abdominal discomfort related to intraperitoneal fluid volume. There was no evidence of bacterial peritonitis. 
found to be 5.9 //min. TBC for this patient dur- 
ing two separate ip infusion courses was 16.6 
and 24.1 //min. This difference in TBC is con- 
sistent with the regional extraction noted. 
Patient 4 received a single IP bolus of FU (1 
gm) on a separate treatment course. The abdo- 
men was loaded with fluid and the LR infused 
as described above before injecting the FU. Peri- 
toneal fluid and venous plasma samples were ob- 
tained over 16 hr and were assayed for FU. Flu- 
orouracil was not detectable in venous plasma 
8 hr later although ip levels were 0.42 pcM at 16 
hr. TBC was calculated from the ratio of dose 
and AUC. AUC was determined by the trape- 
zoidal rule from time zero to the last measur- 
able plasma point and then extrapolated to infin- 
ity (by first order extrapolation). As described by 
Speyer et a1.26 this formula is valid for any lin- 
ear kinetic model regardless of the number of 
compartments. If TBC varies with dose, then 
the drug kinetics are nonlinear. The TBC for 
this patient given the ip bolus was 14.3 //min 
whereas there was a TBC of 29.5 //min during 
the 5-day ip infusion in the same patient. 
The five patients received a total of 20 ip 
infusions of FU. Toxicity was minimal (Table 
II). There was no evidence of systemic toxicity 
(mucositis or myelosuppression), but all pa- 
tients experienced mild abdominal discomfort 
related to the fluid volume infused, e.g., with ip 
fluid loading before FU infusion. Symptomatic 
chemical peritonitis occurred repeatedly in two 
patients who received a total of seven courses. 
There was no change in the distribution of ip 
fluid as determined by TcSC scans and ip levels 
of FU did not change significantly during the 
infusion in these two patients who experienced 
symptomatic chemical peritonitis. One might 
expect such changes to occur if peritoneal sur- 
face characteristics and the PA were affected by 
significant, severe peritonitis. Peritoneal fluid 
was sampled on the third day of each infusion 
for cell count, differential, and bacterial cul- 
ture, and evidence of a mild sterile inflamma- 
tory reaction was present in most patients. 
This study was not specifically designed to 
assess response, and only one patient had read- 
ily measurable disease. The patient with unre- 
sectable gastric cancer had symptomatic malig- 
nant ascites before ip FU. Peritoneal fluid cy- 
tology became negative during the first course 
of ip FU infusion and remained negative on 
subsequent evaluations. This patient also had 
measurable hepatic tumor by CT scan and after 
two cycles had a partial response (more than 
50% reduction in the product of the longest per- 
pendicular diameters of measurable lesions). 
Discussion 
The rationale for ip dosing in patients with 
cancer rests primarily upon achieving high local 
drug concentration in areas where tumor is 
known to be present.8' " Patients at high risk for 
tumor recurrence after resection also might ben- 
efit from adjuvant therapy. If the drug is in- 
jected as an infusion the ratio of the total drug 
exposure (AUC) for the peritoneal cavity to that 
for the systemic circulation is determined by the 
relative clearances from the two spaces. The 
clearance of a drug from a third space is defined 
by the permeability-area product (PA) and is 
related to the molecular weight of the drug 
1 4 0 
2 7 0 
3 2 2 
4 5 3 
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used.8 Thus drugs with high total body clear- 
ance and relatively low PA are rational for ip 
use. Drugs given ip are cleared primarily by the 
portal vein and lymphatics."' 21 Thus for se- 
lected drugs this route may provide an addi- 
tional advantage since hepatic extraction and 
metabolism appears to result in enhanced TBC. 
Other studies have shown that FU has a TBC 
of 1 to 2 //min after IV bolus injection and 3 to 
7 //min when injected as an intravenous infu- 
sion.8. 9' 22 Speyer et al.28 reported a TBC rang- 
ing from 0.9 to 15 //min in 10 patients receiving 
repeated ip exchanges of FU. The nonlinearity 
of FU plasma kinetics after ip exchanges was 
demonstrated as TBC decreased with increasing 
doses. Dose dependent variability in TBC with 
saturable elimination has also been reported for 
hepatic arterial infusions where the selective 
advantage of regional dosing can be diminished 
at higher doses . '2 
Speyer et al." reported a mean PA of 14 
ml/min in patients receiving repeated ip ex- 
changes of FU with relatively short ip dwell 
times." We demonstrated a similar PA for pro- 
tracted ip FU infusions (Table I). The TBC of 
5.9 //min for IV infusion of FU (patient 1) is of 
the range previously reportee 9' 22 and a TBC 
of 14.3 //min after ip bolus of FU (patient 4) is 
within the range reported by Speyer et al." 
Constant ip infusion of FU at the dose-rate se- 
lected for our study appears to provide an im- 
proved regional advantage because of the max- 
imized TBC. 
The plasma levels achieved during these ip 
infusions are in the range of the systemic levels 
after protracted intravenous infusions of FU 
(300 mg/m2/d).12 There has been a recent up- 
surge of interest in the use of protracted infu- 
sions of antimetabolites." Such prolonged in- 
fusions might lead to improved therapeutic 
index since most solid tumors have long dou- 
bling times and only a small proportion of cells 
would be expected to be in the drug sensitive 
DNA synthetic phase at any time. It is possible 
that chronic exposure may maximize selective 
differences in drug uptake and activation while 
killing the increasing fraction of cells ac- 
cumulating in the drug sensitive phase with 
time. 
The ultimate impact of ip infusion remains to 
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be demonstrated. In colorectal cancer, there is 
reason to believe that metastatic cancer in the 
liver initially derives its blood supply from the 
portal venous circulation.' Preliminary reports 
of adjuvant portal venous infusion FU have 
been encouraging.28 This, combined with the 
concern regarding local recurrence of tumor, has 
resulted in considerable interest in ip adjuvant 
therapy as a means of providing high regional 
concentrations of cytotoxic agents. There are 
also data that support therapy of small intra- 
hepatic tumor nodules by either the portal ve- 
nous or hepatic arterial routes.2, 3, 10, 23, 25 since 
the dose limiting toxicity of ip infusion FU is 
not systemic, but regional (i.e. , chemical 
peritonitis), it is conceivable that this modality 
could be combined with systemic chemotherapy 
regimens. The integration of these approaches 
with hepatic arterial infusion chemotherapy, 
where the dose limiting toxicity is chemical 
hepatitis and gastritis ,'° also offers hope for 
improved therapeutic benefit without overlap- 
ping toxicity. The availability of implantable 
devices for convenient access to the peritoneal 
cavity and recent developments in portable in- 
fusion pumps should greatly facilitate further 
clinical investigations in this area. 
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